Drug Profile
Panobacumab - Aridis Pharmaceuticals
Alternative Names: Aerumab; AERUMAB 11; AR 101 (anti-Pa mAb) - Aridis Pharmaceuticals; AR-101 - Aridis Pharmaceuticals; KBPA-101Latest Information Update: 05 Jul 2021
Price :
$50
*
At a glance
- Originator Berna Biotech
- Developer Aridis Pharmaceuticals
- Class Antibacterials; Antitoxins; Monoclonal antibodies
- Mechanism of Action Lipopolysaccharide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Nosocomial pneumonia; Ventilator associated pneumonia
Most Recent Events
- 31 Dec 2020 Aridis Pharmaceuticals has patent protection for panobacumab in Canada, Europe, China, India, Israel, Japan, and USA
- 15 Jun 2020 Aridis Pharmaceuticals plans a phase II/III trial for Nosocomial pneumonia in second half of 2020
- 30 Sep 2019 Panobacumab licensed to the Serum Institute of India, in regions outside of USA, Europe, Canada, UK, China, Australia, New Zealand and Japan (9275697)